Abstract
IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with IDH1/2-mutated post–MPN AML.
Complete remission was achieved in 3/7 patients (1 attaining MRD–) with new IDH1/2-mutated post–MPN AML treated with IDH1/2-i combinations.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Humans
-
Isocitrate Dehydrogenase / genetics
-
Leukemia, Myeloid, Acute* / drug therapy
-
Leukemia, Myeloid, Acute* / genetics
-
Myeloproliferative Disorders* / drug therapy
-
Myeloproliferative Disorders* / genetics
Substances
-
Isocitrate Dehydrogenase
-
IDH1 protein, human